Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with R-GemOx in Relapsed or Refractory DLBCL (ARGO)
NCT03422523Phase 2Terminated
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University Hospital Southampton NHS Foundation Trust. Started May 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03422523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422523.